Introduction: Use of different methods for GnRH administration in ART cycles is a controversy.Microdose regimens in poor- responder patients are very useful and this has been determined by some studies, but it is not clear how this regimen affects patients with first (IVF/ICSI) cycle.
Materials & Methods: In a prospective, randomized, clinical trial study at The Research and Clinical Center for Infertility and Madar Hospital, Yazd, we compared 140 patients who were candidates for IVF/ICSI for the first time. 70 patients received Microdose flare (A Group) and 70 patients were administered GnRH in long luteal PHASE (B group). Number of oocytes, follicles, embryos and the pregnancy outcome were compared in both groups. In microdose group, after administration of 21 contraceptive pills in the last cycle from day 3 , GnRH was given to patients ( 0.05 cc twice a day) and H MG from day 5 (3 vials a day). In long protocol, the patients received 0.5 cc Buserelin daily from day 21 subcutaneously and with the beginning of bleeding , the dosage was decreased to half. HMG was given three times a day. As the follow up of some patients was difficult and their pregnancy outcome was unknown, 14 patients of A group and 3 patients of B group were left out from the study. The data was analyzed by chi-square and T test.
Results: Number of oocytes, embryos and outcome of pregnancy were not different the in two groups. However, the number of mature follicles in long method was higher but not significant statistically.
Conclusion: The Microdose flare regimen thus offers no further advantage for patients with first cycle of IVF/ICSI.